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treatment through time using repeated measures ANCOVA.
RESULTS: The SIS was found to meet psychometric standards
for a valid questionnaire in a GAD population. The efﬁcacy
analysis found four domains (Daily Activities, Emotional Impact,
Energy/Fatigue and Satisfaction with Sleep) consistently demon-
strated signiﬁcantly greater improvements in the zolpidem tar-
trate extended-release group at each timepoint. A quick onset of
treatment effect was evident in all domains of the SIS by Week 2,
with all domains statistically signiﬁcantly demonstrating greater
improvement than placebo. Longitudinal analyses found all SIS
domains to be statistically signiﬁcantly superior to placebo.
CONCLUSION: The SIS adequately meets the criteria for a
validated measure to be used in GAD. The SIS was responsive to
treatment effects in this clinical trial and able to demonstrate
improvements in patient reported outcomes, favoring zolpidem
tartrate extended-release.
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OBJECTIVES: Prior to use in an international study, the Hos-
pital Anxiety and Depression Scale (HADS) underwent linguis-
tic validation in 30 languages. The original scale was developed
in UK English to detect states of anxiety and depression in and
outside hospital and also community settings. A rigorous meth-
odology was required to ensure conceptual equivalence and cul-
tural relevance across different languages. METHODS: The
translation process was conducted by a specialist in each target
country using the following standardized methodology: 1) two
forward translations by professional translators who were
native speakers of the target language and ﬂuent in English; 2)
comparison and reconciliation of the translations by the spe-
cialist in the target country; 3) backward translation by a
native English speaker; 4) comparison of source and backward
version; and 5) review by the developer. The linguistic valida-
tion methodology for some languages deviated slightly from
what is described above, as a translation already existed; the
translation process started at the backward translation step on
the existing version. RESULTS: The translation process
revealed linguistic and conceptual challenges. Translating idi-
omatic expressions often required paraphrasing to convey the
intended meaning whenever a literal equivalent was not con-
ceptually equivalent and culturally relevant. In addition, while
in most language versions it was possible to retain the same
tense as in the original instrument without alteration of
meaning in a few translations it proved necessary to use a dif-
ferent tense to achieve clarity and equivalence of concept.
CONCLUSION: The language versions of the HADS were
established according to a rigorous translation methodology.
The process aims to ensure conceptual equivalence across dif-
ferent language versions to facilitate international comparison
and pooling of data. The linguistic validation process as
a whole supports the advantage of integrating international
feedback on concepts and wording before a questionnaire is
ﬁnalized.
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OBJECTIVES: To evaluate cost-effectiveness of escitalopram
vs. duloxetine in MDD and to identify key drivers of costs in
treatment of depression with escitalopram and duloxetine.
METHODS: An economic evaluation was conducted alongside a
double-blind, randomized study (escitalopram 20 mg/day and
duloxetine 60 mg/day) in outpatients with MDD, aged 18–65
years, with Montgomery Asberg Depression Rating Scale
(MADRS) 26 and Clinical Global Impression Severity (CGI-S)
4, and with reported baseline duration of depressive episode of
12 weeks-1 year. The main cost-effectiveness (CEA) analysis was
conducted on the full analysis set (FAS), with all patients having
1 valid post-baseline health economic assessment. Additional
analyses were conducted on completers set (CS) with complete
follow-up data. Outcomes included Sheehan Disability Scale
(SDS), MADRS total score, treatment response (MADRS
decrease 50%) and remission (MADRS12), and health care
resource use and absenteeism from work evaluated by Health
Economic Assessment. Unit costs of health care services were
obtained from UK published standard sources. RESULTS: In the
main CEA analysis on FAS, escitalopram appears to be more
effective on the SDS scale (95% CI 0.10–3.74) and less costly
than duloxetine (95% CI -1.544 to -247). In additional analy-
ses on CS, patients on escitalopram had 49% lower total cost
compared to duloxetine (p = 0.002), with sick leave contributing
>73% of the total disease cost. Escitalopram was associated with
58% shorter sick leave duration compared to duloxetine
(p < 0.001). Patients with treatment response had 46% shorter
sick leave (p = 0.008), and those achieving remission, sick leave
was 53% shorter (0.002). CONCLUSION: Escitalopram domi-
nates duloxetine on the SDS scale, and is associated with signiﬁ-
cant cost savings compared to duloxetine. Treatment with
escitalopram may reduce sick leaves duration through improved
treatment response, and result in cost savings compared to
duloxetine. The results are in line with other economic studies
showing cost-saving with escitalopram compared to venlafaxine,
another SNRI.
RESPIRATORY DISORDERS—Clinical Outcomes Studies
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OBJECTIVES: Primary pulmonary hypertension (PPH) is a dis-
order with limited treatment options. Sildenaﬁl, an oral phos-
phodiestrase type-5 (PD-5) inhibitor and a pulmonary vasodilator,
is likely to be beneﬁcial in patients with primary pulmonary
hypertension,. we hypothesized that a single dose of Sildenaﬁl
could acutely reduce peak pulmonary artery pressure and improve
echocardiographic diameters of right heart. METHODS: We
studied 12 consecutive patients with PPH (10 patients with New
York Heart Association functional class 222, and 2 patients with
functional class22). After initial echocardiographic evaluation, a
100 mg oral single dose of Sildenaﬁl was added to previous
A306 Abstracts
medication of all patients and 1 hour after that echocardiograpdic
parameters was measured again, and the results were compared.
RESULTS: Peak pulmonary artery pressure and pulmonary accel-
eration time (PAT) signiﬁcantly improved 1 hour after 100 mgoral
single dose of Sildenaﬁl (p < 0.005, 95% CI 5.41–22.93 and
p = 0.005 95% CI -12.89–2.95 respectively). In addition
although the right heart dimensions (right atrium & ventricle)
showed a trend toward improvement, but were not statistically
signiﬁcant (p = 0.135, p = 0.08 respectively). CONCLUSION:
These results suggest that Sildenaﬁl has a acute signiﬁcant
improvement effect on PAP and PAT in patients with PPH.
RESPIRATORY DISORDERS—Cost Studies
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OBJECTIVES: Community Acquired Pneumonia (CAP) is a
leading cause of hospitalisation and mortality in industrialised
countries. This study was an economic evaluation comparing
moxiﬂoxacin with a combination of levoﬂoxacin plus ceftriaxone
in patients hospitalised with CAP in Germany. METHODS: The
MOTIV trial was a multinational, prospective, randomized,
double-blind study in adults with CAP requiring hospitalisation
and parenteral antibiotic therapy. Patients were randomised to
either moxiﬂoxacin (N = 368), or levoﬂoxacin plus ceftriaxone
(N = 365) and received sequential treatment with intravenous
followed by oral antibiotics for 7–14 days. The primary effective-
ness endpoint was clinical response 5–7 days after completion of
treatment. Resource use recorded included length of stay, ward
type, investigations and procedures performed and dose and
frequency of study drug used. Costs were calculated from a
German hospital perspective, drug costs were taken from the Rote
Liste and other costs from a recent publication. A stochastic
sensitivity analysis was performed. RESULTS: Mean age was 65
years (range 18–101) and 58% of patients had severe CAP. The
percentage of patients reporting clinical response (moxiﬂoxacin:
80%, comparator: 84%) met criteria for clinical equivalence so a
cost-minimisation analysis was performed. Mean per patient cost
was €2190 (95% CI: €1954, €2463) for the moxiﬂoxacin group,
and €2619 (95% CI: €2422, €2832) for the comparator group,
difference (-€430, 95%CI: -€740, -€138).Medication costs were
signiﬁcantly lower for moxiﬂoxacin than comparator (-€470,
95% CI: -€522, -€421) but accounted for only 15–30% of total
costs. Subgroup analysis of patients with COPD, cardiovascular
disease, microbiologically proven pneumonia, or severe CAP at
baseline produced consistent ﬁndings. Average cost was sensitive
to price paid for study drugs and the daily cost of hospital stay.
CONCLUSION: Treatment with moxiﬂoxacin was signiﬁcantly
less costly than treatment with levoﬂoxacin plus ceftriaxone, with
no clinically signiﬁcant difference in outcomes achieved.
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OBJECTIVES: Chronic obstructive pulmonary disease (COPD)
is one of the most common chronic and disabling diseases
worldwide. The objectives of this study were to measure the
societal costs of COPD including both direct and indirect costs,
and to estimate the costs for different severity grades of disease
according to changed Swedish guidelines. METHODS: A well-
deﬁned and representative cohort of subjects was used to
examine the costs of COPD. Regular telephone interviews were
done with 212 subjects derived from the OLIN-Studies in
northern Sweden. The severity grades of COPD were divided
according to changed Swedish guidelines, and furthermore Mild
COPD (FEV1 50–79% of predicted) was divided into three
sub-groups, Mild I, II and III. RESULTS: A positive relation-
ship was found between costs and severity grades of COPD,
patients with lower FEV1 % of predicted normal being signiﬁ-
cantly more expensive. Furthermore, the total costs differed sig-
niﬁcantly between the Mild and Pre-clinical severity groups,
from a mean value of SEK 2,513 per subject in the Pre-clinical
group to SEK 28,463 for subjects having FEV1 50–59% of
predicted. The same pattern was found both in direct and indi-
rect costs. Costs for medicines and hospitalisations increased
signiﬁcantly according to FEV1 values in the Mild and Pre-
clinical groups of disease. Costs for disability pension among
indirect costs showed a similar trend. The annual total costs for
Severe (FEV1 < 30% of predicted), Moderate (30–49%), Mild I
(50–59%), Mild II (60–69%), Mild III (70–79%), and Pre-
clinical COPD (>79%) were SEK 183,474, 70,609, 28,463,
11,527, 6,287 and 2,513, respectively. CONCLUSION: Large
variations were found in both the level and breakdown of costs
for COPD, mainly depending on the severity of the disease.
When dividing mild COPD into three different severity grades
of disease, we also found a positive relationship between costs
and severity of disease.
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OBJECTIVES: Assessment of the inﬂuence of nicotine addic-
tion, time of duration and severity of COPD on the frequency of
exacerbations. METHODS: 71 patients with moderate-to-
severe COPD (30 with moderate and 41 with severe) were
enrolled to the study. The smoking status, FEV1 value, time of
duration of COPD, and a one-year history of incidence of exac-
erbations were assessed in all the subjects. The relationship
between the number of exacerbations and the studied features
was evaluated with the regression model. RESULTS: Thirteen
(18.3%) subjects were current smokers, 9 (12.7%) had never
smoked and 50 (70%) had smoked in the past. The mean inten-
sity of cigarette smoking amounted to 34.7 pack-years [CI:
28.7–40.7]. The mean time of COPD duration was 9.2
[CI: 7.7–10.8] years, the mean frequency of exacerbation—3.1
[CI: 2.5–3.6] per year, and the mean % value of FEV1 was
48.1% [CI: 43.7–52.5]. There was no signiﬁcant relationship
between the frequency of exacerbations and the number of
pack-years, smoking status, % value of FEV1 and severity of
COPD. A signiﬁcant correlation was observed between the time
of duration of COPD and average number of exacerbations
(r = 0.31, p = 0.009). It was calculated that each successive year
of COPD duration is associated with 3% accumulation of exac-
erbation risk (determination coefﬁcient—R2 = 0.03). CON-
CLUSION: Long-time duration of COPD is related to a
signiﬁcant increase of the risk of COPD exacerbations—the key
drivers in the overall costs of the disease.
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